Helsinn Group

Welcome! Thank you for connecting to Helsinn’s LinkedIn profile. Helsinn would like to emphasize and make you aware that due to the highly regulated nature of the pharma industry, we cannot engage with you online in sensitive discussions or topics concerning our or other companies’ products and/or services, and/or treatment options. It is best to hold such discussions and to seek guidance privately from your healthcare professional. Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care and rare disease products and a broad development pipeline. Since 1976, Helsinn, focused on the development of new treatments to fulfill more medical needs and on improving the everyday lives of patients, all guided and underpinned by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology and medical devices and has expertise in research and development, manufacturing and commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn launched the Helsinn Investment Fund to support the future of innovation in healthcare and advance early-stage opportunities by providing funding and strategic support to innovative healthcare companies in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland, the US, Monaco and in China as well as a product presence in about 190 countries globally. A modern Group focused on growth and development but also tied to tradition and on the values of a family business: in Helsinn more than 700 employees work not only for the health of the patient, but overall for the quality of life of the person.